Study of New Cancer Drug GI147211
Author Information
Author(s): CJH Gerrits, GJ Creemers, JHM Schellens, P Wissel, AS Th Planting, R Kunka, K Selinger, M de Boer-Dennert, Y Marijnen, M Harteveld, J Verweijl
Primary Institution: Rotterdam Cancer Institute
Hypothesis
GI147211, a new topoisomerase I inhibitor, will show efficacy and manageable side effects in patients with solid tumors.
Conclusion
The study found that GI147211 has dose-limiting toxicities of neutropenia and thrombocytopenia, with a recommended dose of 1.2 mg/m² for further studies.
Supporting Evidence
- GI147211 was administered to patients with solid tumors that did not respond to standard treatments.
- The maximum tolerated dose was determined to be 1.2 mg/m² per day.
- One partial response was observed in a patient with colorectal cancer.
- Neutropenia and thrombocytopenia were the main side effects observed.
- Pharmacokinetic analysis showed a linear relationship between the dose and the area under the curve (AUC).
- Patients experienced mild non-haematological toxicities such as nausea and headache.
- Three patients experienced life-threatening septic complications due to neutropenia.
- The study suggests further investigation of GI147211 in phase II trials.
Takeaway
Doctors tested a new cancer drug called GI147211 on patients, and it caused some side effects but also showed promise in treating cancer.
Methodology
Patients with solid tumors received GI147211 as a 30-minute intravenous infusion daily for 5 days, repeated every 3 weeks, with dose escalation based on toxicity.
Limitations
The study had a small sample size and was limited to patients with solid tumors refractory to standard therapy.
Participant Demographics
{"total_patients":19,"sex_ratio":"10 male, 9 female","median_age":59,"tumor_types":["NSCLC","Colorectal cancer","Sarcoma","Unknown primary","Pancreatic cancer","Breast cancer","Mesothelioma","Oropharyngeal cancer"]}
Want to read the original?
Access the complete publication on the publisher's website